PuraPharm Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

PuraPharm hat ein Gesamteigenkapital von HK$153.2M und eine Gesamtverschuldung von HK$385.1M, was einen Verschuldungsgrad von 251.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen HK$844.0M bzw. HK$690.7M.

Wichtige Informationen

251.3%

Verhältnis von Schulden zu Eigenkapital

HK$385.12m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	HK$42.98m
Eigenkapital	HK$153.24m
Gesamtverbindlichkeiten	HK$690.73m
Gesamtvermögen	HK$843.96m

Jüngste Berichte zur Finanzlage

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

Is PuraPharm (HKG:1498) A Risky Investment?

Sep 28

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Nov 02

Is PuraPharm (HKG:1498) A Risky Investment?

Aug 23

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Apr 01

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

Dec 27

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 1498Die kurzfristigen Aktiva des Unternehmens (HK$349.6M) decken seine kurzfristigen Passiva (HK$571.1M) nicht.

Langfristige Verbindlichkeiten: 1498Die kurzfristigen Vermögenswerte des Unternehmens (HK$349.6M) übersteigen seine langfristigen Verbindlichkeiten (HK$119.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 1498Die Nettoverschuldung im Verhältnis zum Eigenkapital (223.3%) wird als hoch angesehen.

Schulden abbauen: 1498Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 93.3% auf 251.3% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: Obwohl 1498 unrentabel ist, verfügt es über eine ausreichende Cash-Runway für mehr als 3 Jahre, wenn es seinen derzeitigen positiven freier Cashflow beibehält.

Vorhersage Cash Runway: 1498 ist unrentabel, verfügt aber über eine ausreichende Liquiditätsreserve für mehr als drei Jahre, da der freie Cashflow positiv ist und um 29.2% pro Jahr wächst.

PuraPharm Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is PuraPharm (HKG:1498) A Risky Investment?

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Is PuraPharm (HKG:1498) A Risky Investment?

Recent updates

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen